drugset / Trial / NCT01315431
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is being performed to confirm the safety of tesetaxel 27 mg/m2 (Day 1) in combination with capecitabine 2000/mg/m2/day (in 2 equally divided doses on Days 1 through 14) in a 21-day cycle.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-08
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1750 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 27 mg/m2 | Oral |